Table 2.
Characteristic | All patients, n = 340 |
---|---|
Age, median (range), y | 23.5 (1-78) |
Sex, n (%) | |
Male | 197 (57.9) |
Female | 143 (42.1) |
Primary diagnosis, n (%) | |
Hematologic malignancy | 188 (55.3) |
Solid malignancy | 150 (44.1) |
Nonmalignant conditions | 2 (0.6) |
Hematologic malignancies, n (%) | |
ALL | 46 (24.5) |
AML | 11 (5.9) |
CLL | 11 (5.9) |
CML | 8 (4.3) |
NHL | 41 (21.8) |
HL | 54 (28.7) |
MM | 7 (3.7) |
Others | 10 (5.3) |
Solid tumors, n (%) | |
Neuroblastoma | 33 (22.0) |
Glioblastoma | 19 (12.7) |
Lung cancer | 10 (6.7) |
Osteosarcoma | 52 (34.7) |
Head and neck | 16 (10.7) |
Liver tumors | 8 (5.3) |
Others | 12 (8.0) |
Transplant, n (%) | |
Autologous | 99 (29.1) |
Allogeneic | 83 (24.4) |
No transplant | 158 (46.5) |
History of radiation therapy, n = 339 (%) | |
No | 137 (40.4) |
Yes | 202 (59.6) |
Median follow-up (range), mo | 14.9 (<1-183) |
Cumulative follow-up, y | 1027 |
ALL, acute lymphocytic leukemia; AML, acute myelocytic leukemia; CML, chronic myelocytic leukemia; MM, multiple myeloma; TBI, total body irradiation.